August 10, 2026
Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration
August 5, 2026
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
July 29, 2026
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
July 22, 2026
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
July 7, 2026
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
July 2, 2026
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
June 24, 2026
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
June 23, 2026
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
June 22, 2026
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
May 31, 2026
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer